Similar articles

• Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group.

  [No authors listed] [No authors listed] Circulation. 1992 Jul;86(1):100-10. doi: 10.1161/01.cir.86.1.100. Circulation. 1992. PMID: 1535568 Clinical Trial.
• A dilemma for the 1990s. Choosing appropriate experimental animal model for the prevention of restenosis.

  Ferrell M, Fuster V, Gold HK, Chesebro JH. Ferrell M, et al. Circulation. 1992 Apr;85(4):1630-1. doi: 10.1161/01.cir.85.4.1630. Circulation. 1992. PMID: 1532546 No abstract available.
• Delaying disease.

  [No authors listed] [No authors listed] Br J Hosp Med. 1991 Nov;46(5):345. Br J Hosp Med. 1991. PMID: 1835663 Clinical Trial. No abstract available.
• Vascular protection with cilazapril in hypertension.

  Clozel JP, Kuhn H, Hefti F. Clozel JP, et al. J Cardiovasc Pharmacol. 1992;19 Suppl 5:S28-33. J Cardiovasc Pharmacol. 1992. PMID: 1381792 Review.
• Cilazapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiovascular disease.

  Deget F, Brogden RN. Deget F, et al. Drugs. 1991 May;41(5):799-820. doi: 10.2165/00003495-199141050-00008. Drugs. 1991. PMID: 1712710 Review.